Acute and sub-chronic investigations were used to evaluate the toxicity of niosomal preparations. Rats, both male and female, received optimised formulations in single dose acute trial (F1 & F2) and were tracked for 7 days. The least lethal dose for rats when administered orally was determined because no deaths were noted. Subchronic testing with improved formulations (F1 & F2) (oral gavage) was performed on male and female Wistar rats for 14 days, it found no adverse effects on diet, weight gain, mortality, laboratory tests, pathology, or histopathology. While modest differences in body weight increase (%) and a few haematological markers were seen among treated and control animals, these alterations were mainly of a minor nature and are not thought to have any toxicological importance. With both formulations, no-observable-adverse-effects level was established. In conclusion, these safety studies' findings confirm that both formulations are safe.